Table 1.
Characteristics of the patients and outcomes.
| Median (range) or % | Missing data | |
|---|---|---|
| (N=10) | ||
| Characteristics of the patients | ||
| Sex (Female) | 40% (N=4) | 0 |
| Age at onset (years) | 24 (9-50) | 0 |
| Age at transplantation (years) | 32 (26-51) | 0 |
| Number of previous lines of treatment | 4 (2-11) | 0 |
| Active disease before mobilization | 100% | 1 |
| Mobilization | 1 | |
| Cyclophosphamide + G-CSF | 8 | |
| G-CSF alone | 1 | |
| Dose of cyclophosphamide during mobilization | 2 (1.5-4) | 0 |
| Conditioning regimen | 0 | |
| Melphalan 200mg/m² | 5 | |
| Cyclosphosphamide 200 mg/kg –ATG 4.5 mg/kg | 2 | |
| BEAM | 3 | |
| Number of days before engraftment showing: | ||
| Neutrophils > 0.5 x109/L | 11.5 (6-13) | 0 |
| Platelets > 50 x109/L | 14 (13-20) | 1 |
| Complications before Day +100 | ||
| Fever of Unknown Origin | 2 patients/2 episodes | |
| Infectious | 2 patients/2 episodes | |
| Other: | 1 patient/3 episodes | |
| Atrial Fibrillation, Line associated DVT, Depression | ||
| Complications after Day 100 | 0 | 0 |
| Overall Response | 0 | |
| CR | 8 | |
| DDPR | 1 | |
| No response | 1 | |
| Major Relapse (n=1) | 0 | |
| Uveitis | 1 | |
| Minor Relapse (n=2) | 0 | |
| Aphtosis | 2 | |
| Arthralgia | 1 | |
| Median Follow-up (months) | 48 (6-252) | 0 |
ATG, Anti Thymocyte Globulin; BEAM, BCNU – Etoposide-Aracytine- Melphalan; CR, Complete Remission: no evidence for disease activity in patients with daily prednisolone equivalent dosage ≤7.5mg and absence of disease-modifying drugs; DVT, Deep Venous Thrombosis; DDPR, Drug-Dependent Partial Response i.e. any documented clinical and/or laboratory response in patients receiving glucocorticoids ≥7.5mg daily prednisolone dosage and/or disease-modifying drugs. G-CSF, Granulocyte-colony stimulating factor.